Cargando…
Severe pediatric asthma therapy: Dupilumab
Severe asthma is a rare disease affecting <5% of children with asthma. This group of patients account for about 50% of the costs of healthcare for children with asthma. Nowadays, several biological agents are available for pediatric severe asthma. One of these is dupilumab, a monoclonal antibody...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723147/ https://www.ncbi.nlm.nih.gov/pubmed/36483465 http://dx.doi.org/10.3389/fped.2022.963610 |
_version_ | 1784844101380734976 |
---|---|
author | Ferrante, Giuliana Tenero, Laura Piazza, Michele Piacentini, Giorgio |
author_facet | Ferrante, Giuliana Tenero, Laura Piazza, Michele Piacentini, Giorgio |
author_sort | Ferrante, Giuliana |
collection | PubMed |
description | Severe asthma is a rare disease affecting <5% of children with asthma. This group of patients account for about 50% of the costs of healthcare for children with asthma. Nowadays, several biological agents are available for pediatric severe asthma. One of these is dupilumab, a monoclonal antibody against the Interleukin (IL)-4 receptor α-subunit that acts as an antagonist against both IL-4 and IL-13. Dupilumab binds the subunit of the IL-4 receptor, at the level of the subunit shared by the IL-13 receptor, blocking the inflammatory cascade of these two cytokines and the progression of the Th2-inflammatory pathway. The efficacy and safety of dupilumab have been investigated in recently published randomized controlled trials including pediatric patients with asthma. Currently, its use in asthma is approved in adults, adolescents, and children with severe asthma with type 2 inflammation, that are not controlled in spite of high-dose inhaled corticosteroids plus another maintenance drug. Studies are warranted for the evaluation of long-term treatment with dupilumab, including steroid sparing effect and discontinuation of treatment. Further research should also be planned in order to investigate dupilumab potential ability to interfere with the natural history of atopy since early childhood. |
format | Online Article Text |
id | pubmed-9723147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97231472022-12-07 Severe pediatric asthma therapy: Dupilumab Ferrante, Giuliana Tenero, Laura Piazza, Michele Piacentini, Giorgio Front Pediatr Pediatrics Severe asthma is a rare disease affecting <5% of children with asthma. This group of patients account for about 50% of the costs of healthcare for children with asthma. Nowadays, several biological agents are available for pediatric severe asthma. One of these is dupilumab, a monoclonal antibody against the Interleukin (IL)-4 receptor α-subunit that acts as an antagonist against both IL-4 and IL-13. Dupilumab binds the subunit of the IL-4 receptor, at the level of the subunit shared by the IL-13 receptor, blocking the inflammatory cascade of these two cytokines and the progression of the Th2-inflammatory pathway. The efficacy and safety of dupilumab have been investigated in recently published randomized controlled trials including pediatric patients with asthma. Currently, its use in asthma is approved in adults, adolescents, and children with severe asthma with type 2 inflammation, that are not controlled in spite of high-dose inhaled corticosteroids plus another maintenance drug. Studies are warranted for the evaluation of long-term treatment with dupilumab, including steroid sparing effect and discontinuation of treatment. Further research should also be planned in order to investigate dupilumab potential ability to interfere with the natural history of atopy since early childhood. Frontiers Media S.A. 2022-11-22 /pmc/articles/PMC9723147/ /pubmed/36483465 http://dx.doi.org/10.3389/fped.2022.963610 Text en © 2022 Ferrante, Tenero, Piazza and Piacentini. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Ferrante, Giuliana Tenero, Laura Piazza, Michele Piacentini, Giorgio Severe pediatric asthma therapy: Dupilumab |
title | Severe pediatric asthma therapy: Dupilumab |
title_full | Severe pediatric asthma therapy: Dupilumab |
title_fullStr | Severe pediatric asthma therapy: Dupilumab |
title_full_unstemmed | Severe pediatric asthma therapy: Dupilumab |
title_short | Severe pediatric asthma therapy: Dupilumab |
title_sort | severe pediatric asthma therapy: dupilumab |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723147/ https://www.ncbi.nlm.nih.gov/pubmed/36483465 http://dx.doi.org/10.3389/fped.2022.963610 |
work_keys_str_mv | AT ferrantegiuliana severepediatricasthmatherapydupilumab AT tenerolaura severepediatricasthmatherapydupilumab AT piazzamichele severepediatricasthmatherapydupilumab AT piacentinigiorgio severepediatricasthmatherapydupilumab |